Serum paraoxonase 1 activity in patients with iron deficiency anemia

Archives of Medical Science

Volumn 12, Issue 4, 2016, Pages 697-703

  Okuturlar, Yildiz ^a   Gedikbasi, Asuman ^a   Akalin, Nilgul ^a   Gunaldi, Meral ^a   Yilmaz, Deniz ^a   Mert, Meral ^a   Harmankaya, Ozlem ^a   Soylu, Aliye ^a   Karakaya, Pinar ^a   Kumbasar, Abdulbaki ^a  

^a BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Arylesterase; Atherosclerosis; Iron deficiency anemia; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; FERROUS SULFATE; IRON SACCHARATE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; LABORATORY TEST; MALE; PROSPECTIVE STUDY;

EID: 84977275335     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.48730     Document Type: Article

References (37)

1. Clark SF. Iron defciency anemia. Nutr Clin Pract 2008; 23: 128-41.
2. World Health Organization. "Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia." (2008). http://apps.who.int/iris/bitstream/10665/43894/1/9789241596657-eng.pdf. Accessed 01.08.2014.
3. Chonchol M, Christopher N. Hemoglobin levels and coronary artery disease. Am Heart J 2008; 155: 494-8.
4. Teiber J F, Kramer GL, Haley RW. Methods for measuring serum activity levels of the 192 Q and R isoenzymes of paraoxonase 1 in QR heterozygous individuals. Clin Chem 2013; 59: 1251-9.
5. Yildirim K, Uzkeser H, Keles M, et al. Cu/Zn-superoxide dismutase, paraoxonase and arylesterase activities and malondialdehyde levels in patients with familial mediterranean fever. Bratisl Med J 2012; 113: 561-4.
6. Litvinov D, Mahini H, Garelnabi M. Antioxidant and an-ti-infammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 2012; 4: 523-32.
7. Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron iso-maltoside 1, 000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroen-terol 2013; 108: 1877-88.
8. Ozturk E, Balat O, Dikensoy E, et al. No association between serum paraoxonase, arylesterase activities, and hydatidiform mole. Int J Gynecol Cancer 2011; 21: 149-52.
9. Aslan M, Kosecik M, Horoz M, Selek S, Celik H, Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron defciency anemia. Atherosclerosis 2007; 191: 397-402.
10. Koç A, Cengiz M, Ozdemir ZC, Celik H. Paraoxonase and arylesterase activities in children with iron defciency anemia and vitamin B12 defciency anemia. Pediatr He-matol Oncol 2012; 29: 345-53.
11. Kumar D, Rizvi SI. Age-dependent paraoxonase 1 (PON1) activity and LDL oxidation in Wistar rats during their entire lifespan. Sci World J 2014; 2014: 538049.
12. Labib HA, Etewa RL, Gaber OA, Atfy M, Mostafa TM, Bar-soum I. Paraoxonase-1 and oxidative status in common Mediterranean beta-thalassaemia mutations trait, and their relations to atherosclerosis. J Clin Pathol 2011; 64: 437-42.
13. Mackness M, Durrington P, Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004; 15: 399-404.
14. Zhou C, Cao J, Shang L, et al. Reduced paraoxonase 1 activity as a marker for severe coronary artery disease. Dis Markers 2013; 35: 97-103.
15. Takci Z, Bilgili SG, Karadag AS, Kucukoglu ME, Selek S, Aslan M. Decreased serum paraoxonase and arylester-ase activities in patients with rosacea. J Eur Acad Der-matol Venereol 2015; 29: 367-70.
16. Szántó A, Harangi M, Seres I, Paragh G, Zeher M. Decreased human paraoxonase-1 activity in patients with Sjögren's syndrome. Int Immunol 2010; 22: 605-9.
17. Acay A, Erdenen F, Altunoglu E, et al. Evaluation of serum paraoxonase and arylesterase activities in subjects with asthma and chronic obstructive lung disease. Clin Lab 2013; 59: 1331-7.
18. Li Y, Zhai R, Li H, Mei X, Qiu G. Prognostic value of serum paraoxonase and arylesterase activity in patients with sepsis. J Int Med Res 2013; 41: 681-7.
19. Atay AE, Sakar MN, Culcu N, et al. The evaluation of paraoxonase 1 activity in patients with gestational diabetes. Acta Medica Mediterr 2013; 29: 653-7.
20. Gupta N, Gill K, Singh S. Paraoxonases: structure, gene polymorphism and role in coronary artery disease. Indian J Med Res 2009; 130: 361-8.
21. Ren H, Zhou X, Luan Z, et al. The relationship between carotid atherosclerosis, infammatory cytokines, and ox-idative stress in middle-aged and elderly hemodialysis patients. Int J Nephrol 2013; 2013: 835465.
22. Zampetaki A, Dudek K, Mayr M. Oxidative stress in atherosclerosis: the role of microRNAs in arterial remodeling. Free Rad Biol Med 2013; 64: 69-77.
23. She ZG, Chen HZ, Yan Y, Li H, Liu DP. The human paraox-onase gene cluster as a target in the treatment of atherosclerosis. Antioxid Redox Signal 2012; 16: 597-632.
24. Zaki ME, El-Bassyouni H, Kamal S, El-Gammal M, You-ness E. Association of serum paraoxonase enzyme activity and oxidative stress markers with dyslipidemia in obese adolescents. Indian J Endocrinol Metab 2014; 18: 340-4.
25. Aslan M, Horoz M, Sabuncu T, Celik H, Selek S. Serum paraoxonase enzyme activity and oxidative stress in obese subjects. Pol Arch Med Wewn 2011; 121: 181-6.
26. Tabur S, Torun AN, Sabuncu T, et al. Non-diabetic metabolic syndrome and obesity do not afect serum paraox-onase and arylesterase activities but do afect oxidative stress and infammation. Eur J Endocrinol 2010; 162: 535-41.
27. Kostapanos MS, Elisaf MS. High density lipoproteins and type 2 diabetes: emerging concepts in their relationship. World J Exp Med 2014; 4: 1-6.
28. Zhu Y, Huang X, Zhang Y, et al. Anthocyanin supplementation improves HDL-associated paraoxonase 1 activity and enhances cholesterol efux capacity in subjects with hypercholesterolemia. J Clin Endocrinol Metab 2014; 99: 561-9.
29. Jiang XL, Li M, Zhou JG, et al. Plasma paraoxonase-1, oxidized low-density lipoprotein and lipid peroxidation levels in gout patients. Cell Biochem Biophys 2011; 61: 461-6.
30. Rosenblat M, Ward S, Volkova N, Hayek T, Aviram M. VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies. BioFactors 2012; 38: 292-9.
31. González AI, Brites F, Elbert A, et al. Relation between paraoxonase activity, other HDL components and in-fammatory state in hemodialyzed patients. Medicina (B Aires) 2010; 70: 508-12.
32. Schiavon R, Battaglia P, De Fanti E, et al. HDL3-related decreased serum paraoxonase (PON) activity in uremic patients: comparison with the PON1 allele polymorphism. Clin Chim Acta 2002; 324: 39-44.
33. Mackness B, Durrington P, McElduf P, et al. Low paraox-onase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-9.
34. Swarnalatha G, Ram R, Neela P, Naidu MUR, Dakshina Murty KV. Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-ace-tylcysteine in preventing oxidative stress. Saudi J Kidney Dis Transpl 2010; 21: 852-8.
35. Kumbasar A, Gursu M, Kaya C, et al. The Effect of different doses and types of intravenous iron on oxida-tive stress and infammation in hemodialysis patients. J Nephrol 2012; 25: 825-32.
36. Fishbane S, Kalantar-Zadeh K, Nissenson AR. Serum fer-ritin in chronic kidney disease: reconsidering the upper limit for iron treatment. Semin Dialysis 2004; 17: 336-41.
37. Goddard A F, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron defciency anaemia. Gut 2011; 60: 1309-16.